Drug Patents Expiring in 2032

1. List of Abilify Mycite Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10517507 OTSUKA Communication system with enhanced partial power source and method of manufacturing same
Jun, 2032

(9 years from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 13 November, 2017

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

ABILIFY MYCITE KIT family patents

64

United States

18

Japan

11

European Union

9

Canada

9

Israel

7

China

7

Taiwan

6

Hong Kong

6

Australia

4

Brazil

4

Korea, Republic of

4

Mexico

4

Russia

3

India

2

Ukraine

2

South Africa

2

Denmark

1

Cyprus

1

Portugal

1

Spain

1

Slovenia

1

Poland

2. List of Abraxane drug patents

ABRAXANE's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9393318 BRISTOL MYERS SQUIBB CO Methods of treating cancer
Mar, 2032

(8 years from now)

US9597409 BRISTOL MYERS SQUIBB CO Methods of treating cancer
Mar, 2032

(8 years from now)

US9393318

(Pediatric)

BRISTOL MYERS SQUIBB CO Methods of treating cancer
Sep, 2032

(9 years from now)

US9597409

(Pediatric)

BRISTOL MYERS SQUIBB CO Methods of treating cancer
Sep, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
Pediatric Exclusivity (PED) Jun 6, 2023

Drugs and Companies using PACLITAXEL ingredient

Market Authorisation Date: 07 January, 2005

Treatment: Treatment of lung cancer

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of ABRAXANE before it's patent expiration?
More Information on Dosage

ABRAXANE family patents

7

United States

5

Japan

4

Taiwan

3

New Zealand

2

Canada

2

Korea, Republic of

2

Australia

2

Russia

2

Singapore

2

European Union

1

Cyprus

1

China

1

Portugal

1

Brazil

1

Spain

1

Lithuania

1

Israel

1

Costa Rica

1

Hungary

1

Slovenia

1

Mexico

1

Poland

1

Denmark

3. List of Acetadote drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8722738 CUMBERLAND PHARMS Acetycysteine compositions and methods of use thereof
Apr, 2032

(8 years from now)

Drugs and Companies using ACETYLCYSTEINE ingredient

Market Authorisation Date: 23 January, 2004

Treatment: Method of treating acetaminophen overdose with acetylcysteine solutions

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of ACETADOTE before it's patent expiration?
More Information on Dosage

ACETADOTE family patents

9

United States

1

Australia

1

Malaysia

1

China

1

European Union

4. List of Adzenys Er drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9265737 NEOS THERAPS INC Pharmaceutical composition comprising amphetamines complexed with ion-exchange resin particles
Jun, 2032

(9 years from now)

US8709491 NEOS THERAPS INC Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles
Jun, 2032

(9 years from now)

US9017731 NEOS THERAPS INC Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles
Jun, 2032

(9 years from now)

Drugs and Companies using AMPHETAMINE ingredient

Market Authorisation Date: 15 September, 2017

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE;ORAL

More Information on Dosage

ADZENYS ER family patents

13

United States

1

European Union

5. List of Adzenys Xr-odt drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9265737 NEOS THERAPS Pharmaceutical composition comprising amphetamines complexed with ion-exchange resin particles
Jun, 2032

(9 years from now)

US9017731 NEOS THERAPS Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles
Jun, 2032

(9 years from now)

US8709491 NEOS THERAPS Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles
Jun, 2032

(9 years from now)

Drugs and Companies using AMPHETAMINE ingredient

Market Authorisation Date: 27 January, 2016

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

How can I launch a generic of ADZENYS XR-ODT before it's patent expiration?
More Information on Dosage

ADZENYS XR-ODT family patents

13

United States

1

European Union

6. List of Airduo Digihaler drug patents

AIRDUO DIGIHALER Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561808 TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Jan, 2032

(8 years from now)

US8978966 TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jan, 2032

(8 years from now)

US8714149 TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Feb, 2032

(8 years from now)

US10561808

(Pediatric)

TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Jul, 2032

(9 years from now)

US8978966

(Pediatric)

TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jul, 2032

(9 years from now)

US8714149

(Pediatric)

TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Aug, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
M (M) Jul 9, 2024
Pediatric Exclusivity (PED) Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

AIRDUO DIGIHALER family patents

33

United States

18

Hong Kong

18

Japan

17

European Union

16

Israel

15

China

EA

14

EA

13

Korea, Republic of

12

Spain

12

Poland

12

Denmark

10

South Africa

9

Hungary

6

Canada

4

Cyprus

4

New Zealand

4

Slovenia

4

Australia

3

San Marino

3

RS

3

Portugal

3

Croatia

3

Mexico

2

Brazil

1

Turkey

1

Chile

1

Ukraine

1

Peru

1

United Kingdom

7. List of Akynzeo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11312698 HELSINN HLTHCARE Fosnetupitant chloride hydrochloride having improved stability
May, 2032

(8 years from now)

US10717721 HELSINN HLTHCARE Substituted piperaziniums for the treatment of emesis
May, 2032

(8 years from now)

US8426450 HELSINN HLTHCARE Substituted 4-phenyl pyridines having anti-emetic effect
May, 2032

(8 years from now)

US9908907 HELSINN HLTHCARE Substituted piperaziniums for the treatment of emesis
May, 2032

(8 years from now)

US9403772 HELSINN HLTHCARE 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator
May, 2032

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8895586 HELSINN HLTHCARE Methods of treating emesis
May, 2032

(8 years from now)

US10208073 HELSINN HLTHCARE Solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-IUM-(fosnetupitant) and palonosetron hydrochloride in combination with dexamethasone as a neurokinin receptor modulator
May, 2032

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 19, 2023

Drugs and Companies using FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE ingredient

NCE-1 date: 2022-04-19

Market Authorisation Date: 19 April, 2018

Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy

Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS

How can I launch a generic of AKYNZEO before it's patent expiration?
More Information on Dosage

AKYNZEO family patents

11

United States

6

China

3

Japan

2

Lithuania

2

Hungary

1

New Zealand

1

Cyprus

1

San Marino

1

Ecuador

1

RS

1

Uruguay

1

Georgia

1

Portugal

1

Canada

1

Brazil

1

India

1

Dominican Republic

1

Spain

1

Malaysia

1

Croatia

1

Jordan

1

ME

1

Hong Kong

EA

1

EA

1

Korea, Republic of

1

Ukraine

1

Guatemala

1

Chile

1

Israel

1

Costa Rica

1

Peru

1

Slovenia

1

Tunisia

1

Argentina

1

Morocco

1

Australia

1

Philippines

1

Mexico

1

Moldova, Republic of

1

Nicaragua

1

Taiwan

1

South Africa

1

Poland

1

Colombia

1

Singapore

1

Denmark

1

European Union

8. List of Alecensa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9365514 HOFFMANN-LA ROCHE Composition comprising tetracyclic compound
Mar, 2032

(8 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 6, 2024

Drugs and Companies using ALECTINIB HYDROCHLORIDE ingredient

Market Authorisation Date: 11 December, 2015

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of ALECENSA before it's patent expiration?
More Information on Dosage

ALECENSA family patents

4

United States

3

Japan

2

European Union

1

New Zealand

1

China

1

Canada

1

Brazil

1

Spain

1

Malaysia

1

Hong Kong

1

Korea, Republic of

1

Israel

1

Argentina

1

Australia

1

Mexico

1

Poland

1

South Africa

1

Taiwan

1

Russia

1

Singapore

9. List of Aliqopa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10383876 BAYER HEALTHCARE Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
Mar, 2032

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9636344 BAYER HEALTHCARE Substituted 2,3-dihydroimidazo[1,2-C]quinazoline salts
Mar, 2032

(8 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 14, 2024

Drugs and Companies using COPANLISIB DIHYDROCHLORIDE ingredient

Market Authorisation Date: 14 September, 2017

Treatment: Treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

ALIQOPA family patents

3

United States

3

European Union

2

Japan

2

Taiwan

1

New Zealand

1

Cyprus

1

San Marino

1

Ecuador

1

RS

1

Uruguay

1

China

1

Portugal

1

Canada

1

Brazil

1

Dominican Republic

1

Spain

1

Malaysia

1

Croatia

1

Jordan

EA

1

EA

1

Hong Kong

1

ME

1

Korea, Republic of

1

Chile

1

Guatemala

1

Ukraine

1

Israel

1

Costa Rica

1

Peru

1

Slovenia

1

Tunisia

1

Argentina

1

Denmark

1

Cuba

1

Australia

1

Mexico

1

South Africa

1

Poland

1

Colombia

1

Singapore

AP

1

AP

1

Morocco

10. List of Alkindi Sprinkle drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9717740 ETON Treatment of adrenal insufficiency
Nov, 2032

(9 years from now)

Drugs and Companies using HYDROCORTISONE ingredient

Market Authorisation Date: 29 September, 2020

Treatment: Treatment of adrenal insufficiency

Dosage: GRANULE;ORAL

More Information on Dosage

11. List of Amvuttra drug patents

AMVUTTRA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10570391 ALNYLAM PHARMS INC RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases
Nov, 2032

(9 years from now)

US9399775 ALNYLAM PHARMS INC RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases
Nov, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 13, 2027
Orphan Drug Exclusivity (ODE) Jun 13, 2029

Drugs and Companies using VUTRISIRAN ingredient

NCE-1 date: 2026-06-13

Market Authorisation Date: 13 June, 2022

Treatment: Amvuttra is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

AMVUTTRA family patents

16

United States

7

Japan

6

Korea, Republic of

6

European Union

5

China

4

Israel

4

Australia

3

Chile

3

Hong Kong

3

Mexico

3

Singapore

2

New Zealand

2

Canada

2

India

2

Spain

2

Croatia

2

Lithuania

2

Slovenia

2

Argentina

2

Russia

2

Denmark

1

Ecuador

1

RS

1

Portugal

1

Brazil

1

Dominican Republic

1

Malaysia

EA

1

EA

1

Guatemala

1

Ukraine

1

Costa Rica

1

Hungary

1

Peru

1

Tunisia

1

Philippines

1

Nicaragua

1

Poland

1

Colombia

12. List of Aptiom drug patents

Can you believe APTIOM received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9750747 SUNOVION PHARMS INC Treatments involving eslicarbazepine acetate or eslicarbazepine
Aug, 2032

(9 years from now)

Drugs and Companies using ESLICARBAZEPINE ACETATE ingredient

Market Authorisation Date: 08 November, 2013

Treatment: Treatment of partial-onset seizures in a patient suffering from or susceptible to absence seizures; Treatment of partial-onset seizures

Dosage: TABLET;ORAL

How can I launch a generic of APTIOM before it's patent expiration?
More Information on Dosage

APTIOM family patents

2

United States

1

Russia

1

Portugal

1

Canada

1

European Union

13. List of Aristada drug patents

ARISTADA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10226458 ALKERMES INC Pharmaceutical compositions comprising sorbitan esters
Mar, 2032

(8 years from now)

US9034867 ALKERMES INC Pharmaceutical compositions comprising sorbitan esters
Nov, 2032

(9 years from now)

Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient

Market Authorisation Date: 05 October, 2015

Treatment: Treatment of schizophrenia

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

ARISTADA family patents

8

United States

4

Israel

4

Australia

3

New Zealand

3

China

3

Japan

2

Russia

2

European Union

1

Cyprus

1

San Marino

1

RS

1

Portugal

1

Canada

1

Brazil

1

Spain

1

Croatia

1

Lithuania

1

Hungary

1

Slovenia

1

Mexico

1

Poland

1

Denmark

14. List of Armonair Digihaler drug patents

ARMONAIR DIGIHALER Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561808 TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Jan, 2032

(8 years from now)

US8978966 TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jan, 2032

(8 years from now)

US8714149 TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Feb, 2032

(8 years from now)

US10561808

(Pediatric)

TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Jul, 2032

(9 years from now)

US8978966

(Pediatric)

TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jul, 2032

(9 years from now)

US8714149

(Pediatric)

TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Aug, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Jul 9, 2024
New Strength (NS) Jul 9, 2024
Pediatric Exclusivity (PED) Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

ARMONAIR DIGIHALER family patents

33

United States

18

Hong Kong

18

Japan

17

European Union

16

Israel

15

China

EA

14

EA

13

Korea, Republic of

12

Spain

12

Poland

12

Denmark

10

South Africa

9

Hungary

6

Canada

4

Cyprus

4

New Zealand

4

Slovenia

4

Australia

3

San Marino

3

RS

3

Portugal

3

Croatia

3

Mexico

2

Brazil

1

Turkey

1

Chile

1

Ukraine

1

Peru

1

United Kingdom

15. List of Avycaz drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8969566 ALLERGAN Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Jun, 2032

(9 years from now)

US9695122 ALLERGAN Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Jun, 2032

(9 years from now)

US9284314 ALLERGAN Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Jun, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 25, 2020
New Patient Population (NPP) Dec 20, 2025
Generating Antibiotic Incentives Now (GAIN) Feb 25, 2025

Drugs and Companies using AVIBACTAM SODIUM; CEFTAZIDIME ingredient

NCE-1 date: 2024-02-26

Market Authorisation Date: 25 February, 2015

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

AVYCAZ family patents

5

United States

2

China

2

Russia

2

Japan

1

Israel

1

Mexico

1

Australia

1

Spain

1

United Kingdom

1

Taiwan

1

Malaysia

1

Hong Kong

1

Singapore

1

Korea, Republic of

1

Argentina

1

Canada

1

Brazil

1

European Union

16. List of Azstarys drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9079928 COMMAVE THERAP Methylphenidate-oxoacid conjugates, processes of making and using the same
Jul, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 7, 2026

Drugs and Companies using DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE ingredient

NCE-1 date: 2025-05-07

Market Authorisation Date: 07 May, 2021

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

AZSTARYS family patents

7

United States

5

Korea, Republic of

5

Israel

4

Japan

3

Canada

3

Mexico

2

China

2

Spain

2

European Union

1

New Zealand

1

RS

1

Portugal

1

Brazil

1

Malaysia

1

Croatia

1

Chile

1

Lithuania

1

Ukraine

1

Hungary

1

Slovenia

1

Argentina

1

Australia

1

Poland

1

South Africa

1

Russia

1

Colombia

1

Singapore

1

Denmark

17. List of Belbuca drug patents

Can you believe BELBUCA received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9901539 BDSI Transmucosal drug delivery devices for use in chronic pain relief
Dec, 2032

(9 years from now)

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE ingredient

Market Authorisation Date: 23 October, 2015

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: FILM;BUCCAL

How can I launch a generic of BELBUCA before it's patent expiration?
More Information on Dosage

BELBUCA family patents

7

United States

4

Australia

4

Korea, Republic of

3

Singapore

2

New Zealand

2

China

EA

2

EA

1

India

1

Mexico

1

Israel

1

Canada

1

South Africa

1

Hong Kong

1

Japan

1

Ukraine

1

Brazil

1

European Union

18. List of Bijuva drug patents

BIJUVA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11110099 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US10675288 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US10639375 THERAPEUTICSMD INC Progesterone formulations
Nov, 2032

(9 years from now)

US8993549 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US8633178 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US11166963 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US8933059 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US11103513 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US9006222 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US11033626 THERAPEUTICSMD INC Progesterone formulations having a desirable pk profile
Nov, 2032

(9 years from now)

US9301920 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US9114145 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US9114146 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US8846648 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US8846649 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US10206932 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US11103516 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US8993548 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US8987237 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US10052386 THERAPEUTICSMD INC Progesterone formulations
Nov, 2032

(9 years from now)

US10806740 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

Drugs and Companies using ESTRADIOL; PROGESTERONE ingredient

Market Authorisation Date: 28 October, 2018

Treatment: Treatment of menopause symptoms, including vasomotor symptoms

Dosage: CAPSULE;ORAL

How can I launch a generic of BIJUVA before it's patent expiration?
More Information on Dosage

BIJUVA family patents

97

United States

20

Australia

18

Japan

13

European Union

11

Canada

11

Korea, Republic of

10

Mexico

8

Brazil

8

Russia

5

Argentina

4

Israel

2

Spain

2

Croatia

2

Hungary

2

Poland

1

RS

1

Portugal

1

Lithuania

1

South Africa

19. List of Bijuva drug patents

BIJUVA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11529360 MAYNE PHARMA Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

Drugs and Companies using ESTRADIOL; PROGESTERONE ingredient

Market Authorisation Date: 28 October, 2018

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of BIJUVA before it's patent expiration?
More Information on Dosage

BIJUVA family patents

92

United States

19

Australia

17

Japan

12

European Union

10

Canada

10

Korea, Republic of

9

Mexico

8

Brazil

7

Russia

4

Israel

4

Argentina

2

Spain

2

Croatia

2

Hungary

2

Poland

1

RS

1

Portugal

1

Lithuania

1

South Africa

20. List of Biktarvy drug patents

BIKTARVY's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9296769 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

US8754065 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 18, 2026
New Chemical Entity Exclusivity (NCE) Feb 7, 2023
M (M) Feb 24, 2024

Drugs and Companies using BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: 2022-02-07

Market Authorisation Date: 07 February, 2018

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

How can I launch a generic of BIKTARVY before it's patent expiration?
More Information on Dosage

BIKTARVY family patents

5

Japan

4

United States

3

European Union

2

China

2

Australia

1

New Zealand

1

Cyprus

1

San Marino

1

Ecuador

1

RS

1

Uruguay

1

Portugal

1

Canada

1

Brazil

1

India

1

Spain

1

Croatia

1

ME

EA

1

EA

1

Hong Kong

1

Korea, Republic of

1

Lithuania

1

Ukraine

1

Chile

1

Israel

1

Costa Rica

1

Hungary

1

Peru

1

Slovenia

1

Argentina

1

Morocco

1

Mexico

1

Moldova, Republic of

1

Poland

1

Taiwan

1

South Africa

1

Colombia

1

Singapore

AP

1

AP

1

Denmark

21. List of Bortezomib drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8962572 FRESENIUS KABI USA Bortezomib formulations
Nov, 2032

(9 years from now)

Drugs and Companies using BORTEZOMIB ingredient

Market Authorisation Date: 06 November, 2017

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

BORTEZOMIB family patents

3

United States

1

Canada

1

Australia

1

European Union

22. List of Braftovi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9387208 ARRAY BIOPHARMA INC Pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate
Nov, 2032

(9 years from now)

US10258622 ARRAY BIOPHARMA INC Method of treating colorectal cancer by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)pheny1)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl) carbamate
Nov, 2032

(9 years from now)

US9763941 ARRAY BIOPHARMA INC Method of treating melanoma by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate
Nov, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 27, 2023
Orphan Drug Exclusivity (ODE) Jun 27, 2025
New Indication (I) Apr 8, 2023

Drugs and Companies using ENCORAFENIB ingredient

NCE-1 date: 2022-06-27

Market Authorisation Date: 27 June, 2018

Treatment: Braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-ap...

Dosage: CAPSULE;ORAL

How can I launch a generic of BRAFTOVI before it's patent expiration?
More Information on Dosage

BRAFTOVI family patents

7

United States

2

China

2

Japan

2

European Union

1

New Zealand

1

Cyprus

1

RS

1

Portugal

1

Canada

1

Brazil

1

Spain

1

Malaysia

1

Croatia

1

Jordan

1

Hong Kong

EA

1

EA

1

Korea, Republic of

1

Chile

1

Lithuania

1

Guatemala

1

Ukraine

1

Israel

1

Hungary

1

Peru

1

Slovenia

1

Tunisia

1

Argentina

1

Morocco

1

Australia

1

Philippines

1

Mexico

1

Taiwan

1

South Africa

1

Poland

1

Colombia

1

Singapore

1

Denmark

23. List of Brenzavvy drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8987323 THERACOSBIO Crystalline form of benzylbenzene SGLT2 inhibitor
May, 2032

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 20, 2028

Drugs and Companies using BEXAGLIFLOZIN ingredient

NCE-1 date: 2027-01-20

Market Authorisation Date: 20 January, 2023

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

24. List of Bunavail drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8703177 BDSI Abuse-resistant mucoadhesive devices for delivery of buprenorphine
Aug, 2032

(9 years from now)

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 06 June, 2014

Treatment: NA

Dosage: FILM;BUCCAL

How can I launch a generic of BUNAVAIL before it's patent expiration?
More Information on Dosage

BUNAVAIL family patents

13

United States

5

Japan

4

Australia

2

China

2

Singapore

EA

2

EA

2

Canada

1

New Zealand

1

Israel

1

Mexico

1

Spain

1

Korea, Republic of

1

Hong Kong

1

Brazil

1

European Union

25. List of Cabometyx drug patents

CABOMETYX's oppositions filed in EPO
Can you believe CABOMETYX received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11298349 EXELIXIS INC Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
Feb, 2032

(8 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 17, 2028
New Indication (I) Sep 17, 2024

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

Market Authorisation Date: 25 April, 2016

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of CABOMETYX before it's patent expiration?
More Information on Dosage

CABOMETYX family patents

12

United States

5

Korea, Republic of

5

Australia

2

New Zealand

2

Japan

2

Taiwan

2

European Union

1

Georgia

1

China

1

Portugal

1

Brazil

1

Canada

1

Spain

EA

1

EA

1

Israel

1

Hungary

1

Argentina

1

Mexico

1

South Africa

1

Poland

1

Denmark

26. List of Caldolor drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9072710 CUMBERLAND PHARMS Injectable ibuprofen formulation
Mar, 2032

(8 years from now)

US9072661 CUMBERLAND PHARMS Injectable ibuprofen formulation
Mar, 2032

(8 years from now)

Exclusivity Exclusivity Expiration
M (M) Nov 19, 2024

Drugs and Companies using IBUPROFEN ingredient

Market Authorisation Date: 11 June, 2009

Treatment: Methods of making aqueous composition and treating pain, inflammation, fever, patent ductus arteriosis with aqueous composition; Methods of treating pain, inflammation, fever, patent ductus arteriosis...

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

CALDOLOR family patents

6

United States

2

Australia

2

China

1

Spain

1

Peru

1

Chile

1

Hong Kong

1

Korea, Republic of

1

Portugal

1

Denmark

1

Canada

1

European Union

27. List of Calquence drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9290504 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors
Jul, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9758524 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors
Jul, 2032

(9 years from now)

US10239883 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors
Jul, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 31, 2022

Drugs and Companies using ACALABRUTINIB MALEATE ingredient

NCE-1 date: 2021-10-31

Market Authorisation Date: 03 August, 2022

Treatment: Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; Treatment of adult patients with chronic lymphocytic leukemia; Treatment of adult patients with prev...

Dosage: TABLET;ORAL

More Information on Dosage

CALQUENCE family patents

8

United States

6

Japan

5

European Union

4

Australia

3

Lithuania

3

Israel

3

Hungary

2

New Zealand

2

RS

2

China

2

Portugal

2

Spain

2

Croatia

EA

2

EA

2

Korea, Republic of

2

Slovenia

2

Poland

2

Denmark

1

Cyprus

1

Ecuador

1

Turkey

1

Canada

1

Brazil

1

India

1

Dominican Republic

1

Netherlands

1

Norway

1

Malaysia

1

Chile

1

ME

1

Ukraine

1

Guatemala

1

Costa Rica

1

Peru

1

Tunisia

1

Morocco

1

Philippines

1

Mexico

1

Nicaragua

1

Colombia

1

Singapore

28. List of Calquence drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9290504 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors
Jul, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10239883 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors
Jul, 2032

(9 years from now)

US9758524 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors
Jul, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 21, 2026

Drugs and Companies using ACALABRUTINIB ingredient

Market Authorisation Date: 31 October, 2017

Treatment: Treatment of adult patients with previously untreated chronic lymphocytic leukemia in combination with obinutuzumab; Treatment of adult patients with chronic lymphocytic leukemia; Treatment of adult p...

Dosage: CAPSULE;ORAL

How can I launch a generic of CALQUENCE before it's patent expiration?
More Information on Dosage

CALQUENCE family patents

8

United States

6

Japan

5

European Union

4

Australia

3

Lithuania

3

Israel

3

Hungary

2

New Zealand

2

RS

2

China

2

Portugal

2

Spain

2

Croatia

EA

2

EA

2

Korea, Republic of

2

Slovenia

2

Poland

2

Denmark

1

Cyprus

1

Ecuador

1

Turkey

1

Canada

1

Brazil

1

India

1

Dominican Republic

1

Netherlands

1

Norway

1

Malaysia

1

Chile

1

ME

1

Ukraine

1

Guatemala

1

Costa Rica

1

Peru

1

Tunisia

1

Morocco

1

Philippines

1

Mexico

1

Nicaragua

1

Colombia

1

Singapore

29. List of Caspofungin Acetate drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9636407 FRESENIUS KABI USA Caspofungin acetate formulations
Dec, 2032

(9 years from now)

Drugs and Companies using CASPOFUNGIN ACETATE ingredient

Market Authorisation Date: 30 December, 2016

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

CASPOFUNGIN ACETATE family patents

6

United States

1

Cyprus

1

San Marino

1

Spain

1

Hungary

1

Poland

1

Croatia

1

Lithuania

1

Hong Kong

1

Slovenia

1

Portugal

1

Canada

1

Denmark

1

European Union

30. List of Cetylev drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9427421 ARBOR PHARMS LLC Effervescent compositions containing N-acetylcysteine
May, 2032

(8 years from now)

US8747894 ARBOR PHARMS LLC Effervescent compositions containing N-acetylcysteine
May, 2032

(8 years from now)

US9561204 ARBOR PHARMS LLC Effervescent compositions containing N-acetylcysteine
May, 2032

(8 years from now)

Drugs and Companies using ACETYLCYSTEINE ingredient

Market Authorisation Date: 29 January, 2016

Treatment: Method of treating acetaminophen overdose with acetylcysteine solutions

Dosage: TABLET, EFFERVESCENT;ORAL

More Information on Dosage

CETYLEV family patents

4

United States

1

European Union

31. List of Cometriq drug patents

COMETRIQ's oppositions filed in EPO
Can you believe COMETRIQ received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9717720 EXELIXIS Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
Feb, 2032

(8 years from now)

US11298349 EXELIXIS Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
Feb, 2032

(8 years from now)

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

Market Authorisation Date: 29 November, 2012

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

COMETRIQ family patents

12

United States

5

Korea, Republic of

5

Australia

2

New Zealand

2

Japan

2

Taiwan

2

European Union

1

Georgia

1

China

1

Portugal

1

Brazil

1

Canada

1

Spain

EA

1

EA

1

Israel

1

Hungary

1

Argentina

1

Mexico

1

South Africa

1

Poland

1

Denmark

32. List of Contrave drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9248123 NALPROPION Methods of providing weight loss therapy in patients with major depression
Jan, 2032

(8 years from now)

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 10 September, 2014

Treatment: Use of naltrexone and bupropion for chronic weight management for treating overweight or obesity in patients with major depressive disorder

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of CONTRAVE before it's patent expiration?
More Information on Dosage

CONTRAVE family patents

6

United States

2

Australia

2

Russia

2

Korea, Republic of

2

Japan

2

Israel

2

European Union

1

Mexico

1

Canada

1

Spain

1

China

1

Brazil

33. List of Copiktra drug patents

Can you believe COPIKTRA received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE46621 SECURA Processes for preparing isoquinolinones and solid forms of isoquinolinones
May, 2032

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9840505 SECURA Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof
Jan, 2032

(8 years from now)

US11312718 SECURA Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one
Jan, 2032

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 24, 2023
Orphan Drug Exclusivity (ODE) Sep 24, 2025

Drugs and Companies using DUVELISIB ingredient

NCE-1 date: 2022-09-24

Market Authorisation Date: 24 September, 2018

Treatment: For the treatment of patients with follicular lymphoma (fl); For the treatment of patients with chronic lymphocytic leukemia (cll) and/or small lymphocytic leukemia (sll)

Dosage: CAPSULE;ORAL

More Information on Dosage

COPIKTRA family patents

9

United States

3

Taiwan

3

European Union

2

Korea, Republic of

2

Japan

2

Peru

2

Argentina

2

Australia

2

Singapore

1

New Zealand

1

China

1

Canada

1

Brazil

1

Spain

1

Chile

1

Hong Kong

1

Ukraine

1

Israel

1

Philippines

1

Mexico

1

South Africa

1

Russia

1

Denmark

34. List of Cotempla Xr-odt drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9089496 NEOS THERAPS INC Compositions comprising methylphenidate complexed with ion-exchange resin particles
Jun, 2032

(9 years from now)

US9072680 NEOS THERAPS INC Compositions comprising methylphenidate complexed with ion-exchange resin particles
Jun, 2032

(9 years from now)

Drugs and Companies using METHYLPHENIDATE ingredient

Market Authorisation Date: 19 June, 2017

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

How can I launch a generic of COTEMPLA XR-ODT before it's patent expiration?
More Information on Dosage

COTEMPLA XR-ODT family patents

13

United States

1

European Union

35. List of Cycloset drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9700555 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(8 years from now)

US8613947 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(8 years from now)

US11000522 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(8 years from now)

US10688094 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(8 years from now)

US9522117 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(8 years from now)

US9192576 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(8 years from now)

US8431155 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(8 years from now)

US9993474 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(8 years from now)

Drugs and Companies using BROMOCRIPTINE MESYLATE ingredient

Market Authorisation Date: 05 May, 2009

Treatment: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 4...

Dosage: TABLET;ORAL

More Information on Dosage

CYCLOSET family patents

11

United States

3

Australia

3

European Union

2

Mexico

2

Spain

1

Uruguay

1

Hong Kong

1

Korea, Republic of

1

Japan

1

Argentina

1

Canada

1

Brazil

36. List of Daybue drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9212204 ACADIA PHARMS INC Treatment of rett syndrome using glycyl-L-2-methylprolyl-L-glutamic acid
Jan, 2032

(8 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Mar 10, 2030
New Chemical Entity Exclusivity (NCE) Mar 10, 2028

Drugs and Companies using TROFINETIDE ingredient

NCE-1 date: 2027-03-11

Market Authorisation Date: 10 March, 2023

Treatment: Treatment of rett syndrome or a symptom thereof

Dosage: SOLUTION;ORAL

More Information on Dosage

37. List of Defitelio drug patents

DEFITELIO's oppositions filed in EPO